Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00467506

Acronym

RIT in MTC

Enrollment

Unknown

Registered

2007-04-30

Start date

2004-05-01

Completion date

2011-01-01

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Neoplasms

Keywords

Recurrence of medullary thyroid carcinoma: abnormal calcitonin level and biomarkers doubling time lower than 5 years after initial surgery

Brief summary

Phase II clinical trial assessing efficacy and toxicity of pretargeted radioimmunotherapy using anti-CEAxanti-DTPA bispecific antibody and di-DTPA-131I peptide in patients with reccurrence of medullary thyroid carcinoma (abnormal calcitonin level and biomarkers doubling time lower than 5 years)

Interventions

DRUGbispecific antibody and di-DTPA-131I

Study design

Allocation

NON_RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* 18 -75 years * Karnofsky ≥ 70% * Histological diagnosis of medullary thyroid carcinoma * Calcitonin serum level Ê 100 pg/ml and Calcitonin or CEA doubling time £ 5 years * Normal liver and renal functions * Granulocytes ≥ 1500/mm3 and platelets ≥ 150 000/mm3 * No immunization * Consent form signed

Countries

France

Contacts

PRINCIPAL_INVESTIGATORFrancoise Bodere, MD

Nantes University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 15, 2026